# Aadi Bioscience

Source: https://onco.cc/companies/aadi-bioscience/  
OnCo record `aadi-bioscience` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Aadi Bioscience won approval for Fyarro, the albumin-bound sirolimus that treats the rare sarcoma PEComa, then sold it and renamed itself Whitehawk Therapeutics to develop antibody-drug conjugates.

## Summary

Aadi Bioscience developed nab-sirolimus (Fyarro, ABI-009), an mTOR inhibitor bound to albumin nanoparticles for better tumour delivery. The FDA approved it in November 2021 for malignant perivascular epithelioid cell tumour, the first drug for that sarcoma; the PRECISION 1 trial tested it in tumours with TSC1 or TSC2 alterations. In 2025 Aadi sold Fyarro to Kaken Pharmaceutical, in-licensed three antibody-drug conjugates from WuXi Biologics and Hangzhou DAC, and became Whitehawk Therapeutics.

## Fields

- Kind: Company
- Last checked: 2026-09-17
- Also known as: Whitehawk Therapeutics; Aadi Bioscience, Inc.; NASDAQ:AADI
- Tags: drug-maker
- HQ: Los Angeles, California
- Type: biotech
- Website: https://www.aadibio.com/
- Ticker: NASDAQ:AADI

## Sources

- Official website: https://www.aadibio.com/

## Connected records

- drugs: [Sirolimus protein-bound particles](https://onco.cc/drugs/sirolimus-albumin-bound/)

---
JSON: https://onco.cc/api/v1/entities/aadi-bioscience.json